Global

Sy Chyi Yeoh looks at some of the practical considerations faced by Chinese firms looking to expand overseas.

Funding will be used to further develop CC Bio’s microbiome editing technologies, which harness potent enzymes derived from bacterial viruses to seek out and destroy harmful and disease-causing bacteria.

Chairman of the Harvard China Fund, Dr. William C. Kirby, talks about the potential impact on multinational western pharma firms of disruption in China.

Liva Healthcare’s Philipp M. Schäfer talks about the company’s ambitions to drive a positive behavior change in type 2 diabetes.

Rory Mullen outlines Ireland’s importance to multinational pharma in the changing EU landscape.

Report claims an imbalance in influence of tech-transfer decisions.

Cliodhna McDonough-Stevens looks at what the COVID-19 pandemic might mean for the future of cell and gene therapy across Europe.

Wesam Badran looks at how the UK NHS can collaborate with pharma and med-tech partners to encourage digital innovation.

Summits, proposals outline advice on response to future pandemics.

How pharma firms assess their readiness for IDMP (Identification of Medicinal Products) is important for meeting compliance requirements and ensuring they are prepared for the digital product information management future, writes Adnan Jamil.

Andaman7 and Afrisda, Inc. sign partnership agreement to support digital health implementation in Africa.

Pandemic triggers urgency around supply chain initiatives.

The European Commission’s Genetically Modified Organism (GMO) legislation hurts Europe’s ability to attract clinical trials and delays patient access to transformative medicines, say European industry associations.

Becton, Dickinson and Company is to build a $200 million high-tech manufacturing facility in Zaragoza, Spain.

With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.

The progress and stumbling blocks in building a formal EU system.

The drive for “vaccine equity” around the world is bolstering efforts to limit patent protections on innovative medicines and vaccines to combat the global pandemic.

Rosanne Rotondo talks to Pharm Exec about recent breakthroughs in the Novartis Foundation-initiated Leprosy Post-Exposure Prophylaxis and the work of Novartis’ other Global Health Flagship Programs.

Draft plan looks beyond the immediate European health challenges.

Latest proposal explores boosting the powers of the EMA.

Rajit Kamal, Vice President, Asia Pacific for DePuy Synthes, a Johnson & Johnson company, offers recommendations for those wishing to secure an expatriate assignment with their company.

The European Medicines Agency (EMA) has published a guide to implementing IDMP data standards that will be ”a game changer” for the life sciences sector. Remco Munnik, who has been working with the EU focus group creating the EU IDMP Implementation Guide version 2, provides the inside track on the implications for life sciences companies.

Post-Brexit, the UK’s MHRA is looking to join Project Orbis, a global program to speed up patient access to innovative cancer treatments. This article looks at the implications of Project Orbis for commercialization in the UK and the key considerations for industry in considering the project as a pathway.

Donald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.

Can private sector serve public interests in battling rare diseases?